🇺🇸 FDA
Pipeline program

ORIC-114 Dose 1 + amivantamab

ORIC-114-05

Phase 1 small_molecule active

Quick answer

ORIC-114 Dose 1 + amivantamab for Solid Tumors is a Phase 1 program (small_molecule) at Oric Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
Oric Pharmaceuticals
Indication
Solid Tumors
Phase
Phase 1
Modality
small_molecule
Status
active

Clinical trials